Neuropsychopharmacology (2013) 38, 2735–2736 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Corrigenda aCaMKII Autophosphorylation Controls the Establishment of Alcohol Drinking Behavior Alanna C Easton, Walter Lucchesi, Anbarasu Lourdusamy, Bernd Lenz, Jalal Solati, Yulia Golub, Piotr Lewczuk, Cathy Fernandes, Sylvane Desrivieres, Ralph R Dawirs, Gunther H Moll, Johannes Kornhuber, Josef Frank, Per Hoffmann, Michael Soyka, Falk Kiefer, The GESGA Consortium, Gunter Schumann, K Peter Giese and Christian P Mu¨ller Neuropsychopharmacology (2013) 38, 2735; doi:10.1038/npp.2013.188 Correction to: Neuropsychopharmacology (2013) 38, Bonn, Germany; 11Department of Psychiatry and Psy- 1636–1647; doi:10.1038/npp.2013.60 chotherapy, University of Du¨sseldorf, Du¨sseldorf, Germany; In this article, the following collaborators of The 12Department of Psychiatry, University of Mainz, Mainz, GESGA Consortium are being added to the byline: Jens Germany; 13Addiction Research Group at the Department of Treutlein1, Sven Cichon2,3,4,5, Monika Ridinger6, Manuel Psychiatry and Psychotherapy, LVR Hospital Essen, Uni- Mattheisen2,7,8, Stefan Herms2,3,5, Norbert Wodarz6, Peter versity of Duisburg-Essen, Essen, Germany; 14Department Zill9, Wolfgang Maier10, Rainald Mo¨ssner10, Wolfgang of Psychiatric Pharmacogenetics, Max-Planck-Institute of Gaebel11, Norbert Dahmen12, Norbert Scherbaum13, Chris- Psychiatry, Munich, Germany; 15Department of Molecular tine Schma¨l1, Michael Steffens7, Susanne Lucae14, Marcus Psychology, Max-Planck-Institute of Psychiatry, Munich, Ising15, Bertram Mu¨ller-Myhsok16, Markus M No¨then2,3,17, Germany; 16Department of Statistical Genetics, Max-Planck- Karl Mann18, and Marcella Rietschel1 Institute of Psychiatry, Munich, Germany; 17German Center 1Department of Genetic Epidemiology in Psychiatry, for Neurodegenerative Diseases (DZNE), Bonn, Germany; Central Institute of Mental Health, Medical Faculty Man- 18Department of Addictive Behavior and Addiction Medi- nheim/Heidelberg University, Heidelberg, Germany; 2De- cine, Central Institute of Mental Health, Medical Faculty partment of Genomics, Life and Brain Center, University of Mannheim/Heidelberg University, Heidelberg, Germany. Bonn, Bonn, Germany; 3Institute of Human Genetics, University of Bonn, Bonn, Germany; 4Institute of Neu- roscience and Medicine (INM-1), Research Center Juelich, 5 Juelich, Germany; Division of Medical Genetics, Depart- FUNDING AND DISCLOSURE ment of Biomedicine, University Hospital Basel, University of Basel, Basel, Germany; 6Department of Psychiatry, MR has received compensation for advisory activities from University Medical Center Regensburg, University of Lundbeck. NW received funds by Lundbeck and D&A Regensburg, Regensburg, Germany; 7Institute for Medical Pharma for taking part in multi-centre randomized trials. Biometry, Informatics, and Epidemiology, University of He received speaker’s honoraria and travel funds from Bonn, Bonn, Germany; 8Department of Biostatistics, Har- Janssen-Cilag and Essex Pharma. NS received honoraria as vard School of Public Health, Boston, MA, USA; 9Depart- an advisory board member of Sanofi-Aventis and Reckitt- ment of Psychiatry, University of Munich, Munich, Benckiser. He received lecture honoraria from Janssen, Germany; 10Department of Psychiatry, University of Bonn, Lundbeck and Reckitt Benckiser..